The bill aims to enhance diversity in clinical trials in Washington State by establishing policies and programs that encourage participation from underrepresented demographic groups. It mandates the Washington State Review Board to create a diversity in clinical trials program that will compile resources and share information to assist entities conducting clinical trials in increasing participation from these groups. The bill also requires state entities and hospitals receiving National Institutes of Health funding to adopt specific policies for identifying and recruiting underrepresented individuals, including providing information in multiple languages and culturally specific recruitment materials.

Additionally, the bill amends existing laws to include new requirements for the Andy Hill Cancer Research Endowment Program, emphasizing the importance of outreach to underrepresented communities in clinical trials. It outlines the responsibilities of the University of Washington and Washington State University in developing outreach plans and engaging with community organizations to facilitate participation in clinical trials. The bill also includes provisions for the Department of Health to analyze current representation in clinical trials and report recommendations for improvement by December 2023.

Statutes affected:
Original Bill: 43.348.040
Substitute Bill: 43.348.040
Second Substitute: 43.348.040
Bill as Passed Legislature: 43.348.040
Session Law: 43.348.040